Monday's Premium Alert! Analyst Predict 1,607% Upside - See $.50 Biotech Gets $7 Price Target

Want a stock with 1,607% Upside? Of course you want the symbol of this Biotech [New Premium Alert - TC BioPharm (NASDAQ: TCBP)]( Clinical Stage Biotechnology Company Serving Cancer Therapies [Analyst Peg a $7 Price Target on this $.50 cent Biotech]( 10XProTrader Member, Kevin Vander here with "10XProTrader" delivering you your new premium alert for Mondays 10/23 trading session which is TC Biopharm (NASDAQ: TCBP). Your new premium alert is just around the corner for you. STOP! This stock is currently trading at approx. $.50 per share, and has a 12-month analyst target of $7.00 per share! What stock do you know of right now that has a $1,607% upside potential? Breakthrough cancer therapies offer a lot of hope to patients and their families. A new wave of therapies is based on a unique type of immune cells, called gamma delta T cells, has the potential to treat cancer with stronger responses and fewer side effects. Gamma delta T cells are gaining attention fast! These immunotherapies based on T cells, are becoming a huge trend in the treatment of cancer, which makes this emerging company one to put high on your radar! I just uncovered a little-known biotech company by the name of TC Biopharm (Ticker: TCBP) that trades on the NASDAQ at approx. $.50 cents per share. TCBP is an early mover in a monumental biotech arena that is attracting big money and lots of attention from Wall Street analysts. How much attention exactly? Bullish Catalyst H.C. Wainwright Analyst Issued a Buy rating on TC Biopharm with a price target of $7.00. [Initiating with Buy Rating and $7.00 PT]( According to H.C. Wainwright Analyst, TC Biopharm (NASDAQ: TCBP) has 1607% upside potential, based on the analysts’ price target. About TC Biopharm TC Biopharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and viral infections with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC Biopharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer. TC Biopharm Is The First Company to Conduct Phase II Clinical Trials Oncology TC Biopharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Robust Development Pipeline And Significant IP/Patent Portfolio TC BioPharm also maintains a robust pipeline for future indications in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma-delta T cells and owns their manufacturing facility to maintain cost and product quality controls. There Are Several Catalysts in Play Right Now The stock is trading just under $.50/share and has Wall Street analyst predicting bullish upside potential to as high as $7.00/share 12 - month forecast! H.C. Wainwright issued an Analyst report putting a $7.00 price target on TC Biopharm (NASDAQ: TCBP). That Equates to a Potential Upside of 1,607% (Based on Wall Street Analyst) > [See Stock Price Forecast of $7.00 or 1,607% Potential Upside]( < In the biopharma space, cancer is king. Some of the biggest biopharma deals of the last few years have centered on targeted cancer treatments. The largest drug delivery-related acquisition ($1.9 BIL) took place last year between Amgen (NSDQ:AMGN) and Five Prime Therapeutics (NSDQ:FPRX) to support the former's strategy for international expansion and add to its oncology portfolio. And take Juno Therapeutics as another example. Founded in Seattle in 2013 to develop immunotherapy drugs, the company was acquired in 2018 by Celgene, a Biotech giant, for a whopping $9 BIL. Did you know that the FDA's time to approve cancer drugs in the decade ending in 2018 was 48% shorter than it was for treatments in other therapeutic fields? Immunotherapies that show the potential to revolutionize Cancer treatment could be a top priority for the FDA. TC Biopharm (NASDAQ: TCBP), a company that has only recently debuted on the NASDAQ, is developing groundbreaking, pioneering, and disruptive therapies with unrivaled applicability to a wide range of cancers and infectious diseases! Whether the market was up, down, or sideways, there has been a flurry of biopharma companies hitting the public equity markets as the search for coronavirus-related innovation in treatments and vaccines has led to increased public and investor interest in the industry. TC Biopharm Announces Grant Funding Collaboration University of London EDINBURGH, Scotland, Sept. 5, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is proud to announce it has entered into a collaboration agreement with Queen Mary University of London (QMUL) to research the therapeutic potential of gamma-delta T cells for the treatment of mucosal infections. The collaboration recently received grant funding from The Impact Fund arm of QMUL. TC BioPharm will be working in conjunction with Dr. Neil McCarthy's lab out of QMUL. "We are grateful for the support from the Queen Mary University of London Impact Fund and appreciate Dr. McCarthy and his team taking this initiative on with enthusiasm," said Bryan Kobel, CEO of TC BioPharm. "Dr. McCarthy's lab is a leading institution in the gamma delta field focusing on gut health and microbial infections, a great area of interest for TCB. This is an exciting oppor∙tunity for our company and QMUL, the collaboration is a good starting point for both groups with the potential to extend into future engagements and asset spinoffs, while simultaneously expanding the TCB-008 platform into new indications. We believe the data set here and in future endeavors will further showcase the therapeutic benefit of the gamma delta T-cells centering around their role in immunotherapy's future. "My team is excited about working with TC Biopharm to explore the anti-microbial potential of γδ cell therapies," stated Dr. McCarthy. "Our data suggests this could be a promising approach to preventing gut barrier damage in context of mucosal infection and inflammation. We look forward to learning more from this new collaboration and exploring novel routes for translating γδ cell potency into the clinic." TC Biopharm (NASDAQ: TCBP) Positions Itself With Incredible Leadership For Maximum Upside Potential What if there was a revolutionary way to potentially kill tumor cells? A way that isn't getting nearly enough attention as it should... The biopharma space is a treasure hunt for investors who scope the markets for promising companies that may hold the future of cancer treatment in their hands. TC Biopharm therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach! What TCBP is doing could be a game-changer for cancer treatment moving forward... Unlike the alpha beta T cells commonly used in CAR-T immunotherapy, gamma delta T cells play a role in the innate immune response, which constitutes the first, faster line of defense of the immune system. [Human gamma delta T cells]( (GDT cells) have extraordinary properties, including the capacity for tumor cell killing. These cells have the potential to overcome many problems in cancer therapy, especially for tumors with no known treatment. GDT cells constantly monitor the body for signs of biological stress, such as cancerous or infected cells, and are one of the first lines of defense against disease. How do they do this? By detecting changes in the cells, mediated by a complex series of events, the effect of which is common across all cancers and infections. H.C. Wainwright Analyst Target Price Representing 1,607% Upside Potential [Advantages of using GDT Cells as a Cell Therapy Vehicle]( - They activate a wider immune response through antigen presentation and cytokine/chemokine release. - They are completely safe for healthy cells and will not kill them, even when introduced at very high numbers. - They are naturally cytotoxic via a number of different mechanisms. - They are primed to infiltrate tissue, seeking sites of cellular stress and are biologically equipped to enter, reside and survive in a hostile tumor environment. - The GDT cell receptor is not MHC-restricted. This means that if GDT cells from a donor are transferred to a patient, the GDT cells don’t recognize the patient’s body as foreign and don’t cause graft versus host disease (GvHD). This makes them ideal for allogeneic “off the shelf” therapies. - They can be gathered from healthy donors, expanded to very high numbers, banked and frozen, using our validated GMP methods, providing a readily available starting material for manufacturing multiple products. H.C. Wainwright Analyst Target Price Representing 1,607% Upside Potential TCBP - Clinical Expertise with a Game - Changing Approach - TCBP's broad platform technology allows the company to design specific therapies to treat a broad range of cancers and infectious diseases with "off the shelf” allogeneic gamma delta T cell (GDT) products. - The company is the leader in developing gamma-delta T cell therapies and the FIRST company to conduct phase II/pivotal clinical studies in oncology. - The company's lead candidate, TCB002, is in phase 1 for acute myeloid leukemia. TCBP is also developing a cell therapy for COVID-19! - TCBP is conducting two clinical trials for its unmodified gamma-delta T cell product ImmuniStim - a phase II/III pivotal trial in treatment of acute myeloid leukemia and a Phase I trial in treatment of COVID-19 patients. - ImmuniStim uses the company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. - The company also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns its manufacturing facility to maintain cost and product quality controls. - The company's stepwise approach to clinical development has enabled TCBP to take a logical, safer, and more agile approach to their clinical trials! By starting with an autologous, unmodified gamma delta product, the company was able to establish safety prior to entering the clinic in 2018 with their unmodified allogeneic product. Now, TCBP's focus is on clinical development and refinement of products based on the ideal GDT vehicle with a proprietary genetic CAR-T arsenal to fight a range of cancers. TCBP - Exciting Oppor∙tunities Exist for the Massive Cancer Market [View Analyst Target Price Representing 1,607% Upside From Here]( Cancer is a curse, undoubtedly, but it is also a growth market for investors. - According to Precedence Research, the global cancer drug market size is expected to be worth around $272 BIL by 2030 from at $136.2 BIL in 2020, growing at a CAGR of 7.2% from 2021 to 2030. - The American Cancer Society has found that over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. - According to researchers at Penn State College of Medicine, in 2018 the top 15 types of cancer cost the U.S. more than $156 BIL. The National Cancer Institute projects that cancer-related medical costs will skyrocket to $246 BIL by the end of this decade. It is the increasing awareness regarding the availability of various new therapies to treat cancer that is fueling the demand for cancer drugs and treatments among global cancer patients. TCBP is the latest contender in the enormous biopharma space that includes giants like Bristol-Myers Squibb and Pfizer... The company's focus on ground-breaking T-cell therapy could quickly catapult it to the frontline. TCBP is on a mission to develop safer, less expensive treatments that could target more cancers and potentially save more lives! Analysts are anticipating that large drug makers will have big piles of ca∙sh to deploy this year, which could lead to some major mergers and acquisitions. According to a recent interview with CEO of the Company, Bryan Kobel “The Company is preparing to expand into the UK, while also working on launching their Phase 1B in the US. "There is an oppor∙tunity here to really change how cancer is treated." TC Biopharm (NASDAQ: TCBP) New Focus Is To Really Target FDA Clinical Trials "MD Anderson is the world's leading oncology clinic and we were able to sign a significant agreement with them working with the immunotherapy lab," said Kobel, noting the Company's additional research collaborations. "We are expecting some fruition from them this year," added Kobel. "The new focus of the company is to really target FDA clinical trials," he continued. "We have been able to execute on a number of initiatives over the last twelve months, which are now bearing fruit, and that is only going to continue." Conclusion: The Company has taken huge steps forward recently, placing them in an excellent position for rapid growth, all of which indicate the Company's huge growth potential! I'm urging you and all of my 10X members to conduct your own research, and add TCBP to the top of your watch list immediately. Be ready Monday morning at the opening bell! I will be updating you in the morning before the market opens. 10X Your Wealth, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. We have never received stock in TCBP, nor have we traded it. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.